Life Sciences Pharma

Japan is the world’s third largest economy and second largest pharmaceutical market. As a mature economic market with a rapidly aging population, Japan presents a tremendous growth opportunity for pharmaceutical companies. By 2020 the Japan pharma market is estimated to be worth around US $80 Billion, with the global market estimated around US $1 Trillion. Stringent regulations and protectionist economic structures demand expert leadership for the companies who choose to operate in Japan. Such leaders need an established network in industry and government, the highest level of business acumen, and a rare international perspective which permits them to lead a firm in this remarkable market.

Japanese firms are legitimate heavyweight competitors to foreign capital firms, with Japanese pharmaceutical organizations comprising 3 of the top 25 firms globally, and 8 of the top 50. Japan also has a very robust environment for bioventures and R&D. As these firms look to expand and compete globally, finding the right leadership and talent for the 21st century becomes more vital.

Since its inception in 2000, Ingenium Group has been at the forefront of the Japan pharmaceutical industry. We have long standing relationships with key players and organizations and have a unique cultural understanding of the domestic Japanese dynamic coupled with the global dynamic. Our attention to detail along with an adherence to the highest standards makes us a trusted partner in this competitive and intricate marketplace.

Please contact Ingenium to meet our Pharmaceutical team and learn about the expertise they offer you.

Partner: Greg Leviton